MedMen Enterprises Past Earnings Performance
Past criteria checks 0/6
MedMen Enterprises's earnings have been declining at an average annual rate of -51.2%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been declining at an average rate of 17.4% per year.
Key information
-51.2%
Earnings growth rate
-16.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -17.4% |
| Return on equity | n/a |
| Net Margin | -119.3% |
| Last Earnings Update | 25 Mar 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How MedMen Enterprises makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 25 Mar 23 | 120 | -143 | 75 | 0 |
| 24 Dec 22 | 128 | -140 | 84 | 0 |
| 24 Sep 22 | 134 | -129 | 97 | 0 |
| 25 Jun 22 | 141 | -150 | 112 | 0 |
| 26 Mar 22 | 146 | -95 | 124 | 0 |
| 25 Dec 21 | 142 | -89 | 122 | 0 |
| 25 Sep 21 | 134 | -118 | 113 | 0 |
| 26 Jun 21 | 132 | -97 | 110 | 0 |
| 27 Mar 21 | 126 | -220 | 120 | 0 |
| 26 Dec 20 | 138 | -221 | 140 | 0 |
| 26 Sep 20 | 151 | -177 | 174 | 0 |
| 27 Jun 20 | 155 | -177 | 203 | 0 |
| 28 Mar 20 | 161 | -44 | 218 | 0 |
| 28 Dec 19 | 148 | -51 | 241 | 0 |
| 28 Sep 19 | 138 | -76 | 256 | 0 |
| 29 Jun 19 | 120 | -68 | 267 | 0 |
| 30 Mar 19 | 103 | -89 | 280 | 0 |
| 29 Dec 18 | 86 | -81 | 233 | 0 |
| 30 Sep 18 | 59 | -75 | 170 | 0 |
| 30 Jun 18 | 40 | -68 | 105 | 0 |
| 31 Mar 18 | 21 | -42 | 38 | 0 |
| 31 Dec 17 | 7 | -28 | 24 | 0 |
| 30 Sep 17 | 4 | -19 | 16 | 0 |
| 30 Jun 17 | 3 | -15 | 12 | 0 |
Quality Earnings: MMEN is currently unprofitable.
Growing Profit Margin: MMEN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MMEN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MMEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MMEN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: MMEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.